Last reviewed · How we verify

Vifor and EPO

Kunshan First People's Hospital Affiliated to Jiangsu University · FDA-approved active Small molecule

Vifor and EPO is a Iron replacement agent and erythropoiesis-stimulating agent (ESA) Small molecule drug developed by Kunshan First People's Hospital Affiliated to Jiangsu University. It is currently FDA-approved for Iron deficiency anemia, Anemia of chronic kidney disease, Anemia associated with chronic disease. Also known as: iron-supplemented combined EPO group.

Vifor is an intravenous iron replacement therapy that replenishes iron stores, while EPO (erythropoietin) stimulates red blood cell production to treat anemia.

Vifor is an intravenous iron replacement therapy that replenishes iron stores, while EPO (erythropoietin) stimulates red blood cell production to treat anemia. Used for Iron deficiency anemia, Anemia of chronic kidney disease, Anemia associated with chronic disease.

At a glance

Generic nameVifor and EPO
Also known asiron-supplemented combined EPO group
SponsorKunshan First People's Hospital Affiliated to Jiangsu University
Drug classIron replacement agent and erythropoiesis-stimulating agent (ESA)
TargetIron (ferric ion) and erythropoietin receptor (EPOR)
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Vifor (ferric carboxymaltose) delivers iron directly to the body to correct iron deficiency, which is essential for hemoglobin synthesis. EPO acts as a hematopoietic agent that binds to erythropoietin receptors on bone marrow progenitor cells, stimulating erythropoiesis and increasing red blood cell count. Together, they address both iron availability and erythrocyte production in anemia management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vifor and EPO

What is Vifor and EPO?

Vifor and EPO is a Iron replacement agent and erythropoiesis-stimulating agent (ESA) drug developed by Kunshan First People's Hospital Affiliated to Jiangsu University, indicated for Iron deficiency anemia, Anemia of chronic kidney disease, Anemia associated with chronic disease.

How does Vifor and EPO work?

Vifor is an intravenous iron replacement therapy that replenishes iron stores, while EPO (erythropoietin) stimulates red blood cell production to treat anemia.

What is Vifor and EPO used for?

Vifor and EPO is indicated for Iron deficiency anemia, Anemia of chronic kidney disease, Anemia associated with chronic disease.

Who makes Vifor and EPO?

Vifor and EPO is developed and marketed by Kunshan First People's Hospital Affiliated to Jiangsu University (see full Kunshan First People's Hospital Affiliated to Jiangsu University pipeline at /company/kunshan-first-people-s-hospital-affiliated-to-jiangsu-university).

Is Vifor and EPO also known as anything else?

Vifor and EPO is also known as iron-supplemented combined EPO group.

What drug class is Vifor and EPO in?

Vifor and EPO belongs to the Iron replacement agent and erythropoiesis-stimulating agent (ESA) class. See all Iron replacement agent and erythropoiesis-stimulating agent (ESA) drugs at /class/iron-replacement-agent-and-erythropoiesis-stimulating-agent-esa.

What development phase is Vifor and EPO in?

Vifor and EPO is FDA-approved (marketed).

What are the side effects of Vifor and EPO?

Common side effects of Vifor and EPO include Hypertension, Headache, Injection site reactions, Nausea, Thrombotic events (with EPO).

What does Vifor and EPO target?

Vifor and EPO targets Iron (ferric ion) and erythropoietin receptor (EPOR) and is a Iron replacement agent and erythropoiesis-stimulating agent (ESA).

Related